Repligen Corp (RGEN) is a publicly traded Healthcare sector company. As of September 10, 2026, RGEN trades at $164.98 with a market cap of $9.51B and a P/E ratio of 220.59. RGEN moved -2.15% today. Year to date, RGEN is +0.73%; over the trailing twelve months it is +39.06%. Its 52-week range spans $100.99 to $188.73. Analyst consensus is strong buy with an average price target of $179.67. Rallies surfaces RGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Repligen Corp (RGEN) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. RGEN moved -2.15% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $164.98 |
| Market Cap | $9.51B |
| P/E Ratio | 220.59 |
| EPS | $0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $188.73 |
| 52-Week Low | $100.99 |
| Volume | 939.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $785.10M |
| Net Income | $41.54M |
| Gross Margin | 53.84% |
11 analysts cover RGEN: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $179.67.